Altimmune (ALT) Interest Coverage Ratio (2010 - 2026)
Altimmune (ALT) reported Interest Coverage Ratio of 22.7 for Q1 2026, up 99.9% year-over-year from 11.36 in Q1 2025, and up 31.18% on a QoQ basis from 32.98 in Q4 2025.
Altimmune (ALT) has 17 years of Interest Coverage Ratio data on file, last reported at 22.7 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 99.9% year-over-year to 22.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.86 (up 99.67% YoY) and the FY2025 annual result came in at 57.76, up 99.5% from the prior year.
- Interest Coverage Ratio advanced to 22.7 in Q1 2026 per ALT's latest filing, from 32.98 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 126.2 in Q4 2022 and bottomed at 26794.0 in Q1 2024.
- The 5-year median for Interest Coverage Ratio is 777.24 (2023), against an average of 8405.47.
- The widest annual swing landed in 2023, when Interest Coverage Ratio plunged 13421.66%; it then surged 99.9% in 2026.
- Tracing ALT's Interest Coverage Ratio over 5 years: stood at 126.2 in 2022, then sank by 13421.66% to 16811.5 in 2023, then tumbled by 47.91% to 24866.0 in 2024, then soared by 99.87% to 32.98 in 2025, then soared by 31.18% to 22.7 in 2026.
- Per Business Quant, the three latest ALT Interest Coverage Ratio figures stand at 22.7 (Q1 2026), 32.98 (Q4 2025), and 42.14 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -22.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.70 |
| Dec 31, 2025 | -32.98 |
| Sep 30, 2025 | -42.14 |
| Jun 30, 2025 | -86.83 |
| Mar 31, 2025 | -21,815.00 |
| Dec 31, 2024 | -24,866.00 |
| Sep 30, 2024 | -4,127.83 |
| Jun 30, 2024 | -26,745.00 |
| Mar 31, 2024 | -26,794.00 |
| Dec 31, 2023 | -16,811.50 |
| Sep 30, 2023 | -777.24 |
| Jun 30, 2023 | -9,003.50 |
| Mar 31, 2023 | -10,879.50 |
| Dec 31, 2022 | 126.20 |
| Sep 30, 2022 | -386.75 |
| Jun 30, 2022 | -313.77 |
| Mar 31, 2022 | -314.50 |
| Dec 31, 2021 | 386.85 |
| Sep 30, 2021 | -1,006.18 |
| Jun 30, 2021 | -1,130.18 |
| Mar 31, 2021 | -1,238.42 |
| Dec 31, 2020 | -5,504.25 |
| Sep 30, 2020 | -8,054.60 |
| Jun 30, 2020 | -5,567.71 |
| Mar 31, 2020 | -3,876.26 |
| Sep 30, 2019 | -14,911.88 |
| Jun 30, 2019 | -4,747.17 |
| Mar 31, 2019 | -3,146.70 |
| Dec 31, 2018 | -214.73 |
| Sep 30, 2018 | -24.31 |
| Jun 30, 2018 | -2,829.67 |
| Mar 31, 2018 | -6,890.30 |
| Dec 31, 2017 | -6,171.20 |
| Sep 30, 2017 | -13,204.94 |
| Jun 30, 2017 | -41.29 |
| Mar 31, 2017 | -74.54 |
| Dec 31, 2016 | -571.76 |
| Sep 30, 2016 | -509.09 |
| Jun 30, 2016 | -166.58 |
| Mar 31, 2016 | -1,194.70 |
| Dec 31, 2015 | -154.45 |
| Sep 30, 2015 | -167.73 |
| Jun 30, 2015 | -147.97 |
| Mar 31, 2015 | 45.85 |
| Dec 31, 2014 | -70.82 |
| Sep 30, 2014 | -85.15 |
| Jun 30, 2014 | -20.69 |
| Dec 31, 2013 | -65.75 |
| Sep 30, 2013 | -35.62 |
| Jun 30, 2013 | -14.81 |
| Mar 31, 2013 | -10.93 |
| Dec 31, 2012 | -12.34 |
| Sep 30, 2012 | -15.91 |
| Jun 30, 2012 | -13.10 |
| Mar 31, 2012 | -525.33 |
| Dec 31, 2011 | -77.14 |
| Sep 30, 2011 | -304.26 |
| Jun 30, 2011 | -203.08 |
| Mar 31, 2011 | -294.13 |
| Dec 31, 2010 | -2.32 |
| Sep 30, 2010 | -3.56 |
| Jun 30, 2010 | -6.01 |